A Phase 1, Open-Label, Dose-Escalation Study of PRT1419, a Selective Induced MCL-1 Inhibitor, in Patients With Advanced/Metastatic Solid Tumors

Gerald S. Falchook, Manish R. Patel, Meredith McKean, Alexander Philipovskiy, Neha Bhagwat, Rachel Chiaverelli, William Sun, Michael Fossler, William Novotny, Michael Kurman, Sarah Rowe, Deborah Hunter, Mohammed Milhem